



**28 OCTOBER 2021**

**eTheRNA immunotherapies conference attendance for November 2021**

**Niel (Belgium)** eTheRNA immunotherapies NV ('eTheRNA'), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences for November 2021:

**[9th International mRNA Health Conference](#)**

**9-10 November 2021**

Stefaan De Koker, Vice President of Discovery, will be speaking as part of the 'Vaccines Session', on Wednesday 10th November 2021 from 11:15-11:35am CET. His presentation will focus on 'Cancer vaccines candidates based on optimised mRNA-LNP formulations tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells'.

**[TIDES Europe Oligonucleotides & Peptide Therapeutics](#)**

**15-17 November 2021**

George Dakwar, Senior Scientist Drug Product Development, and David Ricketts, Director of Business Development, will be in attendance.

**[European Mediscience Awards](#)**

**16 November 2021**

eTheRNA has been shortlisted in the 'Emerging Star Award' category. Steven Powell, Chief Executive Officer, and Johanna Madero, Communications Coordinator, will be attending the Awards Ceremony.

**[Jeffries London Healthcare Conference](#)**

**16-19 November 2021**

Mathieu Lane, Chief Financial Officer and President of eTheRNA immunotherapies Inc., will be in attendance.

**[8th China Healthcare Summit](#)**

**16-19 November 2021**

Steven Powell, Chief Executive Officer, will give a corporate presentation and highlight eTheRNA's expansion in Asia as part of the 'Belgium Presenting Company Track'. The presentation will be available on demand in the Conference Portal [link](#).

**[The Antwerp Forum - Linking Business between China and Europe](#)**

**30 November 2021**

Steven Powell, Chief Executive Officer, will be speaking as part of the 'Current challenges for doing business with China and how to move towards resilient and sustainable post-pandemic times' panel on Tuesday 30<sup>th</sup> November 2021 from 10:50am-12:00pm CET.



### **About eTheRNA immunotherapies**

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its mRNA chemistry, antigen identification, lipid chemistry and delivery and process engineering platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA's R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.

### **Contact Information**

media@etherna.be